Email Updates

You are here

AVAC in the News

  • Crises have a habit of accelerating history, including the pace of technological advancement. The COVID-19 pandemic is no exception. Vaccines were developed, safely but with unprecedented efficiency, less than a year after the WHO declared a global pandemic.

    February 23, 2021
    Vaccines Today
  • In a bid to include ethical considerations in the HIV prevention trial process UNAIDS and the World Health Organisation recently launched a new guidance document for ethical consideration for HIV prevention trials. The guidance among other things, calls for the inclusion of communities that live in settings where trials are taking place as equal partners.

    February 12, 2021
    General
    Devex
  • This year's HIV Research for Prevention (HIVR4P) virtual conference featured a large number of sessions examining PrEP usage and discontinuation rates among a variety of users, especially in Africa. Many of the presentations looked at factors that worked as incentives to keep taking PrEP. There is interest in this because, despite higher initiation rates in a larger number of countries than ever before, the retention rates (also called persistence rates) of people in PrEP programmes in the region remain very low.

    February 8, 2021
    aidsmap
  • Results of a “proof of concept” study presented at the virtual 4th HIV Research for Prevention Conference last week showed that one particular broadly neutralising monoclonal antibody (bNAb) – called VRC01 – prevented HIV infection in over 70 percent of people exposed to strains of HIV that is sensitive to this particular bNAb.

    February 8, 2021
    Antibody Related Research, Cure
    Spotlight
  • HIV science has advanced but policies and programmes have been slow to respond towards ending AIDS, said Mitchell Warren, co-chair of the global conference on HIV Research for Prevention (HIVR4P) and Executive Director of AVAC.

    February 7, 2021
    CNS
  • Global funding for COVID-19 vaccine development has exceeded 10 times in less than a year the amount allocated for HIV and TB research and development in 11 years.

    February 6, 2021
    General
    The International News
  • When Wasiu spoke to Devex in 2018 about his HIV-positive status and the statuses of his three wives, the two living with him in Nigeria had tested positive for HIV while the one in the United States was HIV-negative due to distance and her ability to access pre-exposure prophylaxis, or PrEP.

    February 5, 2021
    Devex
  • Nearly 1 million people are now taking pre-exposure prophylaxis (PrEP), medicine that can slash the risk of HIV infections. While early use of the drug was mostly limited to Western nations, the number of users in sub-Saharan Africa (SSA) has now drastically increased, accounting for more than half of the world’s PrEP users.

    February 2, 2021
    New Scientist
  • Despite the incredible efficacy of oral pre-exposure prophylaxis (PrEP) and 78 countries currently offering PrEP in some form, its effectiveness at reducing HIV incidence in the real world has been dependent on far-reaching factors that go beyond how well PrEP is able to prevent HIV acquisition at a cellular level: political leadership, quality health services and funding.

    February 1, 2021
    aidsmap
  • South Africa is ahead of local targets in rolling out the HIV prevention pill. Meanwhile, options for HIV prevention are expanding — though the devil is in the detail of getting medicines to people in a way that works for them.

    January 27, 2021
    Daily Maverick

Pages